Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues

Table 1 Association of RBM5, EGFR, and KRAS proteins with clinicopathological characteristics in 120 pair NSCLC specimens

	Total no. of Patients (%)	RBM5			EGFR			KRAS
	Total no. of Patients (%)	Low(N)	%	P	High(N)	%	P	High(N)	%	P
Characteristic
Gender n
Male	73(61)	56	76.7	0.46	23	31.5	0.597	34	46.6	0.666
Female	47(39)	28	66.7		18	38.3		20	42.6
Age (years)
Less than 60	37(31)	26	70.3	0.996	12	32.4	0.586	16	43.2	0.796
Greaterthanorequalto60	83(69)	58	69.7		29	34.9		38	45.8
Smoking status
Former or Current	84(70)	66	78.6	0.001**	14	38.9	0.475	45	53.6	0.002**
Never	36(30)	18	50		27	32.1		8	22.2
Histology, n
Adenocarcinoma	47(39)	36	76.6	0.206	19	40.4	0.246	17	36.2	0.119
Squamous cell	73(61)	48	65.8		22	30.1		37	50.7
Lymph node Metastasis
Positive	60(50 %)	50	83	0.008**	27	45	0.009**	34	56.7	0.01*
Negative	60(50 %)	34	56.7		14	23.3		20	33.3
Tumor TNM stage
IA	16(13 %)	9	56	0.029**	3	18.7	0.031	2	12.5	0.022*
IB	18(15 %)	11	61		5	27.7		5	27.8
IIA	28(23 %)	17	60.7		6	35.2		7	25
IIB	23(19 %)	17	73.9		10	43.5		10	43.5
IIIA	20(17 %)	17	85		9	45		11	55
IIIB	15(13 %)	13	86.6		8	53.3		9	60

(Low) reduced expression patients.(High) increased expression patients. Values represent asymptotic two-tailed significance with asterisks denoting *P < 0.05 and **P < 0.01, from the Pearson’s Chi-squared test.

ISSN: 1756-9966